C. Daniel Mullins, PhD, chair of pharmaceutical health services research at the School of Pharmacy, University of Maryland, describes the state of pharmacy school curricula related to biosimilars.
Transcript
Biologics and biosimilars are evolving so quickly it's hard for anybody to keep up. From an educational standpoint, every school of pharmacy is trying to change its curriculum as quickly as possible, but if you received a lecture last year and something changes this year, we don’t always get that new information into that third-year or fourth-year class. So I think, as the new pipeline comes through, they’re getting trained in the latest and greatest, but we need continuing education of people who either have already graduated or are further along in their training to make sure that it's not just the next generation, but it's the current generation of pharmacists that are equipped to handle biologics and biosimilars.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.